Skip to content

EPS (Basic) at other companies

Pfizer logo
PfizerPFE
$0.47-9.6%
Eikon Therapeutics, Inc.
 logo
Eikon Therapeutics, Inc. EIKN
-$2.46+90.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$2.15+23.2%
Replimune Group logo
Replimune GroupREPL
-$0.77+2.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$1.11-35.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$0.60-445%

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%
Enterprise value-$7.49M-127%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s EPS (basic)?
OnKure Therapeutics, Inc. (OKUR) reported EPS (basic) of -$1.11 in Q1 2026.
How has OnKure Therapeutics, Inc.'s EPS (basic) changed year-over-year?
OnKure Therapeutics, Inc.'s EPS (basic) increased by 6.7% year-over-year, from -$1.19 to -$1.11.
What is the long-term trend for OnKure Therapeutics, Inc.'s EPS (basic)?
Over 3 years (2021 to 2025), OnKure Therapeutics, Inc.'s EPS (basic) has grown at a -2.8% compound annual growth rate (CAGR), from -$4.80 to -$4.41.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.